Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
- Author:
Jii Bum LEE
1
;
Hyung Soon PARK
;
Sejung PARK
;
Hyo Jin LEE
;
Kyung A KWON
;
Young Jin CHOI
;
Yu Jung KIM
;
Chung Mo NAM
;
Nam Hoon CHO
;
Beodeul KANG
;
Hyun Cheol CHUNG
;
Sun Young RHA
Author Information
- Publication Type:Original Article
- Keywords: Temsirolimus; First-line; Asian; Renal cell carcinoma; Efficacy; Tolerability
- MeSH: Asian Continental Ancestry Group; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Nephrectomy; Prognosis; Prospective Studies; Retrospective Studies
- From:Cancer Research and Treatment 2019;51(4):1578-1588
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naïve Asian patients with metastatic/recurrent nccRCC. MATERIALS AND METHODS: From January 2008 to July 2017, data of treatment-naïve, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end-point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus. RESULTS: Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54%) were papillary type, and other histology subtypes included 11 chromophobes (25%), two collecting ducts (5%), one Xp11.2 translocation (2%), and six others (14%). The median PFS and OS were 7.6 months and 17.6 months, res-pectively. ORR was 11% and disease control rate was 83%. Patients with prior nephrectomy had longer PFS (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.06 to 0.42; p < 0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p < 0.001). Compared to favorable/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12; p=0.005]) and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56; p=0.015]). CONCLUSION: Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate-risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events.
